Breakthrough in Sjogren’s disease: Phase 2 trial reveals efficacy of dazodalibep
In a significant advancement for the treatment of Sjögren’s disease (SjD), a phase 2 clinical trial published in Nature Medicine has demonstrated the efficacy of …
Rheuma Tv
Swan neck deformity
Image type: Swan neck deformity Body site: Fingers Description: Swan neck deformity is a condition that affects the joints in the fingers, leading to serious …
S100 proteins emerge as potential predictive biomarkers for abatacept response in pJIA
A recent study published in Arthritis Research and Therapy has revealed promising findings in the search for predictive biomarkers of treatment response in polyarticular juvenile …
Erythropoietin accelerates rheumatoid arthritis progression by activating neuraminidase 3
In a groundbreaking study published in Annals of the Rheumatic Diseases, researchers have uncovered a novel role of erythropoietin (EPO) in the progression of rheumatoid …
Rheumatoid arthritis inked to increased risk of heart failure, new study reveals
A recent study published in Frontiers in Immunology has unveiled a significant link between rheumatoid arthritis (RA) and an elevated risk of heart failure (HF), …
Ischemic -Vasculitis thrombosis
Image type: Ischemic -Vasculitis thrombosis Body site: Fingers Description: Thromboembolic disease is increasingly recognized in systemic vasculitis, particularly with venous thrombotic events (VTEs) in Behçet’s …
SLAM associated protein-expressing T cells: A new biomarker for lupus nephritis in SLE patients
A recent study published in Frontiers in Immunology identified an expanded population of signaling lymphocytic activation molecule-associated protein (SAP)+ T peripheral helper (TPH) cells in …
Breaking ground in osteoarthritis: Denosumab shows promise in erosive hand OA treatment
A recent phase 2a randomized, double-blind, placebo-controlled clinical trial has provided compelling evidence for the efficacy of denosumab in treating erosive hand osteoarthritis (OA). The …
Upadacitinib shows long-term promise in rheumatoid arthritis treatment: 5-Year SELECT-NEXT study results
A comprehensive five-year study has affirmed the long-term efficacy and safety of upadacitinib (UPA) in treating rheumatoid arthritis (RA). The SELECT-NEXT trial, a phase III …